Ten thousand patients have been treated with the OssDsign AB’s nanosynthetic bone graft, OssDsign Catalyst, the company announced. OssDsign claims the continuous, rapid increase in treated patients is a testament to OssDsign Catalyst’s strong reception in the U.S. market since its launch more than three years ago. 

”With 10,000 patients treated, the adoption of OssDsign Catalyst is clearly accelerating. This is a substantial increase from the 5,000 patients reported in May 2024, highlighting the increasing interest we are seeing from surgeons and hospitals,” OssDsign CEO Morten Henneveld said.

Over the past 16 months, OssDsign has released 10 peer-reviewed clinical and pre-clinical studies as well as white papers that show strong clinical outcomes with OssDsign Catalyst. Notably, the long-term data (24 months) from the TOP FUSION clinical study recently published in the Biomedical Journal of Scientific & Technical Research reveal a 100% spinal fusion rate, improved quality of life, and decreased pain after surgery with OssDsign Catalyst. 

OssDsign Catalyst is a nanosynthetic bone graft that shows rapid and robust bone formation, even in poorly vascularized environments. OssDsign Catalyst’s patented nanocrystalline structure and incorporated silicon ions mimic the body’s natural bone and enable bone formation in the fusion mass center. Consequently, there is a decreased non-union risk, which makes the product applicable for both simple and complex patients.

OssDsign developa and provides next-generation orthobiologics products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities. OssDsign has a strong presence in the U.S. market. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.